Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
BUSINESS
Eisai Licenses Pariet Successor to Zeria
Eisai and Zeria Pharmaceutical announced on August 18 that they have entered into a license agreement for Eisai’s proton pump inhibitor (PPI) E3710. Under the terms of the deal, Eisai will grant Zeria exclusive development and copromotion rights as well…
To read the full story
BUSINESS
- ASKA Snags Japan Rights to Minghui’s TED Therapy
November 5, 2026
- ASKA Starts PIII Trial of Drospirenone for Dysmenorrhea in Japan
November 5, 2026
- ASKA to Acquire Japan Rights to Bayer’s Osteoporosis Drug Wellnara
November 5, 2026
- Nxera Inks US$1.47 Billion Deal with AbbVie for IBD Drug
November 5, 2026
- Mochida Lifts G-Lasta Biosimilar Shipment Curbs after Over 2 Years
November 4, 2026
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…